Vittoria Biotherapeutics, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Vittoria Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to address the limitations of current cell therapy approaches, especially in treating difficult-to-treat diseases in oncology and autoimmune disorders.

Central to its work is the proprietary Senza5™ platform technology, which enhances the effectiveness of engineered T cells by modulating CD5 signaling. The platform features a rapid five-day manufacturing process aimed at improving production efficiency and maximizing T cell stemness, durability, and potency. The company’s lead product candidate, VIPER-101, is undergoing Phase 1 clinical trials for recurrent nodal peripheral T-cell lymphoma. Its pipeline includes therapies targeting solid tumors and autoimmune diseases, demonstrating a commitment to transforming patient treatment options and actively advancing clinical research.